Document text
Principal Investigator: Kristen Keon Ciombor
Organization: VANDERBILT UNIVERSITY MEDICAL CENTER
Fiscal Year: 2024
Award: $462,912
Funding agency: National Cancer Institute
PROJECT SUMMARY/ABSTRACT
Vanderbilt-Ingram Cancer Center (VICC) is a matrix cancer center within Vanderbilt University Medical Center
(VUMC). VICC has been part of the cooperative group system for over 27 years, and a Lead Academic
Participating Site since the inception of the National Clinical Trials Network (NCTN). Throughout the years, we
have integrated our physicians into leadership roles and our basic science into investigator-initiated trials, as
well as enrolled patients onto clinical trials. Additionally, VICC has a long track record of leadership, both
scientific and administrative, within the cooperative groups/NCTN, and helping junior faculty in clinical trial
development. VICC brings great strengths to the NCTN, including two SPORE grants, an EDRN grant, a world
class Institute of Imaging Science, eight highly funded scientific programs and an Early Therapeutics Clinical
Trial Network (ETCTN) grant where successful early phase trials can be integrated into the NCTN. Our
Personalized Cancer Medicine Initiative (PCMI) is dedicated to matching the appropriate therapy to the genetic
changes, or mutations, that are driving the growth of cancers, with an active research component investigating
mechanisms of resistance to targeted therapies. The key informatics of the VICC PCMI is MyCancerGenome,
a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for
patients whose tumors harbor actionable genetic alterations. With the development of PD-1/PD-L1 inhibitors
and novel immune therapies on the horizon, VICC has recruited top researchers in immunology. Those top
researchers in collaboration with other VUMC investigators created the Vanderbilt Institute for Infection,
Immunology and Inflammation (VI4) with an overall mission to train the next generation scientists and
physicians and make fundamental discoveries in the areas of infection biology, immunology and inflammation
with the goal of increasing knowledge and improving human health. VICC clinicians and scientists are
academic leaders in their respective disciplines and will continue to significantly contribute to the NCTN goals
with the objective to improve the outcomes for cancer patients.
The VICC selected Dr. Jordan Berlin, MD, as Principal Investigator to continue leading the efforts of the
institution to integrate its scientific, academic and patient resources into the NCTN. He has been involved
extensively in the cooperative groups/NCTN in conduct of clinical trials, mentorship and leadership. To assist
Dr. Berlin with the conduct of this grant, VICC created two advisory boards, Internal Advisory Board (IAB) and
NCTN Executive Committee (NEC), whose membership includes a broad representation of medical disciplines
and disease interests across VICC and VUMC. The IAB assures the optimal use of the grant, such as budget
review, assuring multidisciplinary involvement, and participation throughout the NCTN. The NEC implements
operational functions, such as trial opening, accrual and mentoring. Operationally, the NEC has actively
managed NCTN trial opening, accruals and participation across disciplines and groups. Both the IAB and NEC
work to integrate VICC science into the NCTN. The VICC Clinical Trials Shared Resource and its NCTN team
ensures that regulatory, biospecimen, radiology and data submissions are timely and highly accurate.
An extensive plan to further advance the integration of the NCTN into the VICC clinical research enterprise and
VICC research into the NCTN is detailed in the grant, including the new appointment of Dr. Berlin to the role of
Associate Director for Clinical Research Strategy and Shared Resources. This is a new role for VICC,
designed to allow coordination of clinical research priorities across all VICC programs and to increase the
translation of VICC science into clinical trials. For this grant, Dr. Berlin’s new role will help to strengthen the
prioritization of NCTN trials across the institution.
Terms: <Academic Medical Centers><Advanced Cancer><Advanced Malignant Neoplasm><Advisory Committees><Alabama><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Appointment><Area><Authorship><Automobile Driving><Award><Basic Research><Basic Science><Berlin><Biology><Breast><Budgets><Cancer Center><Cancer Drug><Cancer Patient><Cancer Treatment><Cancers><Catchment Area><Center for Cancer Research><Cessation of life><Clinical Cancer Center><Clinical Investigator><Clinical Research><Clinical Sciences><Clinical Study><Clinical Trials><Clinical Trials Network><Collaborations><Collection><Communities><Compassion><Comprehensive Cancer Center><Conduct Clinical Trials><Country><Data><Death><Death Rate><Dedications><Department chair><Development><Diagnosis><Discipline><Discipline of obstetrics><Disease><Disorder><ECOG><EDRN><ET-CTN><Early Detection Research Network><Early Therapeutic-Clinical Trials Network><Eastern Cooperative Oncology Group><Education><Education and Outreach><Educational aspects><Ensure><Faculty><Funding><General Radiology><Generalized Growth><Genetic Alteration><Genetic Change><Genetic defect><Goals><Grant><Growth><Gynecology><Health><Human><IRB><IRBs><Image><Immune mediated therapy><Immunologically Directed Therapy><Immunology><Immunotherapy><Incidence><Infection><Inflammation><Informatics><Infrastructure><Institution><Institutional Review Boards><Instruction and Outreach><Investigators><Jordan><Kentucky><Knowledge><Lead><Leadership><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant neoplasm of pancreas><Manuscripts><Medical><Medicine><Mentors><Mentorship><Mission><Modern Man><Mutation><NCI Center for Cancer Research><NCI Organization><National Cancer Institute><National Clinical Trials Network><National Detection Research Network><Neoplastic Disease Chemotherapeutic Agents><Obesity><Obstetrics><PD-1/PD-L1><PD-1/PDL1><PD-L1 inhibitors><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL1 inhibitors><Pancreas Cancer><Pancreatic Cancer><Patient-Centered Care><Patients><Pb element><Phase><Physicians><Prevention><Principal Investigator><Process><Protocol><Protocols documentation><Radiography><Radiology><Radiology Specialty><Research><Research Activity><Research Personnel><Research Priority><Research Resources><Researchers><Resource Sharing><Resources><Roentgenography><Role><Science><Scientist><Services><Site><Specialty><System><Task Forces><Technology><Tennessee><Tissue Growth><Tobacco Consumption><Tobacco use><Training><Training and Outreach><Translational Research><Translational Science><Translations><Tumor-Specific Treatment Agents><Tutoring and Outreach><United States><Universities><University Medical Centers><Work><adiposity><advisory team><anti-cancer drug><anti-cancer therapy><cancer care><cancer clinical trial><cancer genomics><cancer therapy><cancer-directed therapy><corpulence><data deposition><data submission><design><designing><developmental><driving><drug discovery><early phase trial><evidence base><gastrointestinal><genome mutation><heavy metal Pb><heavy metal lead><imaging><imaging science><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><improved outcome><innovate><innovation><innovative><inter-institutional><interest><investigator-initiated trial><malignancy><medical specialties><meeting><meetings><member><mortality rate><mortality ratio><multidisciplinary><neoplasm/cancer><next generation><novel><oncogenomics><oncology clinical trial><ontogeny><pancreatic malignancy><participant enrollment><patient centered><patient enrollment><patient oriented><programmed cell death ligand 1 inhibitors><programmed cell death protein ligand 1 inhibitors><programs><radiologic imaging><radiological imaging><recruit><resistance mechanism><resistant mechanism><social role><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tobacco product use><translation><translation research><translational investigation><tumor><web site><website>